Navios Maritime Partners L.P. reported its financial results for the second quarter ended June 30, 2025, with revenues of $327.6 million, a 4.3% decrease from Q2 2024. Net income for the quarter was $69.9 million, and earnings per common unit were $2.34. For the first half of 2025, revenues decreased by 4.4% to $631.7 million, with adjusted net income at $112.0 million. Adjusted EBITDA for Q2 2025 decreased by $17.2 million to $172.6 million, primarily due to lower time charter and voyage revenues and increased vessel operating expenses.
A significant development was the company's response to the U.S. Department of Treasury’s Office of Foreign Assets Control (OFAC) adding VS Tankers FZE to its Specially Designated Nationals list on July 3, 2025. Navios Partners swiftly terminated bareboat charters for two VLCCs (built in 2020 and 2021) that were chartered to VS Tankers through October 2030 and February 2031, each at a rate of $27,456 net per day. Both vessels were immediately redeployed into a healthy spot market, showcasing the company's operational agility and effective risk management.
The company continued its fleet and financing strategies, agreeing to acquire two scrubber-fitted newbuilding aframax/LR2 tankers for $133.0 million and taking delivery of a 2025-built aframax/LR2 tanker. Navios Partners also agreed to sell two containerships and a transhipper vessel for aggregate gross sale proceeds of $95.5 million. New credit facilities totaling $389.6 million were secured in June 2025 for refinancing and newbuilding financing. As of August 13, 2025, Navios Partners had repurchased 716,575 common units in 2025 for $27.8 million, and maintained a contracted revenue backlog of $3.1 billion through 2037.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.